Shares of CG Oncology Inc. (CGON) plummeted 5.37% in pre-market trading on Monday following the company's announcement of a mixed shelf filing. The late-stage clinical biopharmaceutical company, focused on developing bladder cancer treatments, filed a registration statement on Friday for the potential sale of an unspecified amount of securities.
The mixed shelf filing covers the sale of CG Oncology's common stock, preferred stock, debt securities, and warrants. While the company stated that the proceeds from the offering would be used for general corporate purposes, investors appear concerned about potential dilution of existing shares, leading to the sharp decline in stock price.
This news comes amidst CG Oncology's preparations to participate in the 120th American Urological Association Annual Meeting, where the company is set to present key updates on its lead candidate, cretostimogene grenadenorepvec. Despite the promising clinical developments, the market's negative reaction to the potential share dilution overshadowed any positive sentiment surrounding the company's upcoming presentations.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。